Tricida, Inc.
Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression of CKD.
Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression of CKD.
Tricida, Inc. is a pharmaceutical company with a mission to combat metabolic acidosis and the progression of chronic kidney disease (CKD). The company's flagship drug candidate, veverimer (TRC101), is a non-absorbed, orally-administered polymer designed specifically to address metabolic acidosis in CKD patients. Metabolic acidosis, commonly associated with CKD, is known to expedite the advancement of the disease, elevate the risk of muscle wasting, and contribute to the loss of bone density. Founded in August 2013, Tricida, Inc. boasts a highly experienced management team renowned for their expertise in developing and commercializing therapeutics, particularly in the realm of polymers for treating kidney-related ailments. The company operates within the healthcare and pharmaceutical industries and is headquartered in the United States. Recently, the company secured a significant $125.00M Post-IPO Debt investment as of 19 October 2022, with Hercules Capital as the investor. This substantial investment stands as a testament to the potential and promise that Tricida, Inc. holds in revolutionizing the treatment of metabolic acidosis in CKD patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $125.00M | 1 |
|
19 Oct 2022 |
| Post-IPO Equity | $42.00M | 3 |
|
15 Nov 2021 |
| Post-IPO Debt | $200.00M | - | 22 May 2020 | |
| Debt Financing | $100.00M | 1 |
|
02 Mar 2018 |
| Series D | $57.50M | 8 |
|
08 Nov 2017 |
No recent news or press coverage available for Tricida, Inc..
We care about your data, and we'd love to use cookies make your experience better.
